Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Publication
, Journal Article
Kelley, MJ; Jha, G; Shoemaker, D; Herndon, JE; Gu, L; Barry, WT; Crawford, J; Ready, N
Published in: Cancer Invest
January 2, 2017
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 2, 2017
Volume
35
Issue
1
Start / End Page
32 / 35
Location
England
Related Subject Headings
- src-Family Kinases
- Treatment Outcome
- Treatment Failure
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelley, M. J., Jha, G., Shoemaker, D., Herndon, J. E., Gu, L., Barry, W. T., … Ready, N. (2017). Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Invest, 35(1), 32–35. https://doi.org/10.1080/07357907.2016.1253710
Kelley, Michael J., Gautam Jha, Debra Shoemaker, James E. Herndon, Lin Gu, William T. Barry, Jeffrey Crawford, and Neal Ready. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.” Cancer Invest 35, no. 1 (January 2, 2017): 32–35. https://doi.org/10.1080/07357907.2016.1253710.
Kelley MJ, Jha G, Shoemaker D, Herndon JE, Gu L, Barry WT, et al. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Invest. 2017 Jan 2;35(1):32–5.
Kelley, Michael J., et al. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.” Cancer Invest, vol. 35, no. 1, Jan. 2017, pp. 32–35. Pubmed, doi:10.1080/07357907.2016.1253710.
Kelley MJ, Jha G, Shoemaker D, Herndon JE, Gu L, Barry WT, Crawford J, Ready N. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Invest. 2017 Jan 2;35(1):32–35.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 2, 2017
Volume
35
Issue
1
Start / End Page
32 / 35
Location
England
Related Subject Headings
- src-Family Kinases
- Treatment Outcome
- Treatment Failure
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Female